Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-23T06:18:44.447Z Has data issue: false hasContentIssue false
  • English
  • Français

Hearing results following intratympanic gentamicin perfusion for Ménière's disease

Published online by Cambridge University Press:  28 October 2008

E Kyrodimos ,
I Aidonis  and
A Sismanis
E Kyrodimos*
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
I Aidonis
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
A Sismanis
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
*
Address for correspondence: Dr Efthimios Kyrodimos, Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth University Medical Center, 1201 East Marshall Street, Suite 402, Box 980146, Richmond, VA 23298, USA. E-mail: [email protected] Fax: +1 8048285779
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To evaluate hearing results following intratympanic gentamicin perfusion in patients with Ménière's disease.

Materials and methods:

Middle-ear perfusion of 0.4 ml of gentamicin 40 mg/ml solution was performed in Ménière's disease patients who had previously failed to respond to other medical treatment.

Results:

Between May 1999 and November 2005, 22 patients (mean age 58.5 years) underwent intratympanic gentamicin perfusion. Mean follow up was 30 months. At the first post-perfusion visit (four to six weeks following perfusion), three of the 22 patients (13.63 per cent) had a pure tone average improvement of at least 10 dB, 15 (68.18 per cent) showed no change and four (18.18 per cent) demonstrated a decrease in hearing of more than 10 dB. Regarding speech discrimination scores, one patient (4.54 per cent) exhibited an improvement of at least 15 per cent, 15 (68.18 per cent) showed no change and six (27.27 per cent) showed a decrease of at least 15 per cent. After long-term follow up (12–40 months following perfusion), 10 patients (45.45 per cent) showed stable hearing, and 12 (54.54 per cent) exhibited a pure tone average decrease of more than 10 dB. Six patients (27.27 per cent) showed a speech discrimination score decrease of at least 15 per cent, while 16 (72.72 per cent) had no change. Complete cessation of vertigo was reported by 20 of the 22 patients (90.9 per cent), while two (9.09 per cent) reported episodic vertigo spells.

Conclusion:

Intratympanic gentamicin perfusion provides effective control of vertigo in patients with Ménière's disease. However, significant hearing loss may occur immediately after perfusion; therefore, this treatment should be considered only for patients whose hearing has already been affected by the disease.

Keywords

Meniere's DiseaseGentamicinMiddle EarSensorineural Deafness
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 4 , April 2009 , pp. 379 - 382
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented at European Federation of Otolaryngology Societies (EUFOS), June 30–July 4 2007, Vienna, Austria.

References

1 Cohen-Kerem, R, Kisilevsky, V, Einarson, TR, Kozer, E, Koren, G, Rutka, JA. Intratympanic gentamicin for Meniere's disease: a meta-analysis. Laryngoscope 2004;114:2085–91Google Scholar
2 Garduno-Anaya, MA, Couthino, DT, Hinojosa-Gonzalez, R, Pane-Pianese, C, Rios-Castaneda, LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005;133:285–94Google Scholar
3 Longridge, NS. Meta-analysis of intratympanic gentamicin. Otol Neurotol 2005;26:554Google Scholar
4 Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease, American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:181–5Google Scholar
5 Atlas, JT, Parnes, LS. Intratympanic gentamicin titration therapy for intractable Meniere's disease. Am J Otol 1999;20:357–63Google Scholar
6 Minor, LB. Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy. Am J Otol 1999;20:209–19Google ScholarPubMed
7 Wu, IC, Minor, LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Meniere's disease. Laryngoscope 2003;113:815–20Google Scholar
8 Bertino, G, Durso, D, Manfrin, M, Casati, L, Mira, E. Intratympanic gentamicin in monolateral Meniere's disease: our experience. Eur Arch Otorhinolaryngol 2006;263:271–5Google Scholar
9 Jackson, LE, Silverstein, H. Chemical perfusion of the inner ear. Otolaryngol Clin North Am 2002;35:639–53Google Scholar
10 Silverstein, H, Arruda, J, Rosenberg, SI, Deems, D, Hester, TO. Direct round window membrane application of gentamicin in the treatment of Meniere's disease. Otolaryngol Head Neck Surg 1999;120:649–55Google Scholar
11 Silverstein, H, Rowan, PT, Olds, MJ, Rosenberg, SI. Inner ear perfusion and the role of round window patency. Am J Otol 1997;18:586–9Google Scholar